Search Results - "Janetzki, Jack L"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
  2. 2

    Application of an Integrative Drug Safety Model for Detection of Adverse Drug Events Associated With Inhibition of Glutathione Peroxidase 1 in Chronic Obstructive Pulmonary Disease by Janetzki, Jack L., Pratt, Nicole L., Ward, Michael B., Sykes, Matthew J.

    Published in Pharmaceutical research (01-06-2023)
    “…Background Chronic Obstructive Pulmonary Disease is characterised by declining lung function and a greater oxidative stress burden due to reduced activity of…”
    Get full text
    Journal Article
  3. 3

    Chronic Obstructive Pulmonary Disease Adverse Event Signals Associated with Potential Inhibitors of Glutathione Peroxidase 1: A Sequence Symmetry Analysis by Janetzki, Jack L., Sykes, Matthew J., Ward, Michael B., Pratt, Nicole L.

    Published in Drug safety (2024)
    “…Background and Objective Prior molecular modelling analysis identified several medicines as potential inhibitors of glutathione peroxidase 1 (GPx1) which may…”
    Get full text
    Journal Article
  4. 4

    Innovations in pharmacovigilance studies of medicines in older people by Kalisch Ellett, Lisa M, Janetzki, Jack L, Lim, Renly, Laba, Tracey-Lea, Pratt, Nicole L

    Published in British journal of clinical pharmacology (26-03-2024)
    “…Pharmacovigilance is defined by the World Health Organization as "the science and activities relating to the detection, assessment, understanding and…”
    Get full text
    Journal Article
  5. 5

    Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease—A sequence symmetry analysis approach by Janetzki, Jack L, Sykes, Matthew J, Ward, Michael B, Pratt, Nicole L

    “…What is Known and Objective Proton pump inhibitors (PPIs), used to treat and prevent gastro‐oesophageal conditions, are well‐tolerated but have been associated…”
    Get full text
    Journal Article